UNSPSC 51171719: Zaldaride

This classification denotes an antidiarrheal agent with the molecular formula C26H28N4O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GH66PET6S3, chemically known as (+-)-1-(1-((4-methyl-4h,6h-pyrrolo(1,2-a)(4,1)benzoxazepin-4-yl)methyl)-4-piperidyl)-2-benzimidazolinone but generally known as zaldaride, which bears US NIH Compound Identifier 65909. European Medicines Agency schedules Zaldaride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB00131MIG.

UNSPSC 51171719 Zaldaride (Commodity) covers pharmaceutical products supplied directly to state and local health and human services programs, including correctional supervision agencies, state health commissions, and multistate cooperative purchasing alliances. State and local governments procure under this code for offender drug-screening programs, pharmacy benefit management initiatives, and generic pharmaceutical distribution to correctional facilities, public health agencies, and participating municipalities across cooperative purchasing networks. The work includes specimen collection and laboratory testing services bundled with pharmaceutical supply, formulation of direct-to-manufacturer prescription fulfillment models outside traditional pharmacy benefit manager channels, and provision of generic multi-source pharmaceuticals and over-the-counter products meeting cGMP and Drug Supply Chain Security Act compliance. Issuing bodies span county-level correctional supervision departments, state health and human services commissions, and multistate cooperative purchasing organizations; Texas entities (Collin County Community Supervision and Corrections Department, Texas Health and Human Services Commission) and Minnesota's multistate cooperative (MMCAP, administered by the Minnesota Department of Administration) represent recent active buyers.

Geographic activity centers on Texas and Minnesota, with MMCAP's reach extending to participating jurisdictions including Oregon. Representative recent opportunities include Collin County Community Supervision and Corrections Department's RFP 2026-327 for offender specimen collection and drug testing services (due July 23, 2026; estimated contract value $600,000; two-year term with three optional one-year renewals), requiring staffing of two collection sites in Plano and McKinney, SAMHSA or CAP lab certification, and approximately 25,031 annual tests at per-test pricing; Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) seeking vendor capabilities for direct-to-manufacturer prescription programs outside existing PBM and GPO arrangements; and Minnesota MMCAP's RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products (due March 26, 2026; effective July 1, 2026; two-year term with optional extensions), requiring cGMP and DSCSA compliance, relationships with specified wholesalers, and per-unit pricing with 3 percent administrative fees.